Skip to Main Content

Coronavirus (COVID-19) Resource Center

This guide provides valuable resources for both, Healthcare Professionals (physicians, nurses and practitioners) and Health Consumers about the COVID-19 outbreak and recent research related to this topic.


Below is a list of articles related to vaccines, and updated regularly:

Click here for older articles


  • Hammond J, et al. "Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19." April 3, 2024 N Engl J Med 2024;390:1186-1195 VOL. 390 NO. 13 

  • Thompson M.G., et al. "Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." February 22, 2024 N Engl J Med 2024; 390:772 

  • Ali S, et al. "Anti-Melanoma Differentiation-Associated Protein-5 and Anti-Polymyositis/Scl-75 Antibody-Associated Interstitial Lung Disease Triggered by COVID-19 Vaccine: A Case Report." Annals of Internal Medicine: Clinical CasesVolume 3, Issue 2 published February 06, 2024 

  • Kanai M, et al. "Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial." Lancet Infect Dis. 2023 Dec 20 doi: 10.1016/S1473-3099(23)00650-3. 

  • Zhou J, et al. "Post–COVID-19 Vaccine Myopericarditis in a Transgender Man Undergoing Gender-Affirming Testosterone Therapy." Annals of Internal Medicine: Clinical CasesVolume 3, Issue 1 January 2024. January 16, 2024  

  • Valdes Y, et al. "COVID-19 Vaccination and Reproductive Health: a Comprehensive Review for Healthcare Providers." Reprod. Sci. (2023). Published: 27 December 2023.

  • Kuhn T, et al. "Evaluating the impact of short animated videos on COVID-19 vaccine hesitancy: An online randomized controlled trial." Internet Interventions, Volume 35, 2024, Available online 1 December 2023.

  • Liu X, et al. "Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial." Lancet Respir Med. 2023 Dec;11(12):1075-1088. Epub 2023 Nov 15. 

  • Chi H, et al. "The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report." Life (Basel). 2023 Oct 21;13(10):2094. 

  • Chi H, et al. "The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report." Life (Basel). 2023 Oct 21;13(10):2094. (Systematic review) 

  • Weng ZY, et al. "Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis." Front Med (Lausanne). 2023 Oct 9;10:1275843. eCollection 2023. 

  • Lepage C, et al. "Persuasive COVID-19 vaccination campaigns on Facebook and nationwide vaccination coverage in Ukraine, India, and Pakistan." PLOS Glob Public Health. 2023 Sep 27;3(9):e0002357. eCollection 2023. 

  • Manothummetha K, et al. "Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis." Blood Adv. 2023 Sep 26;7(18):5624-5636. 

  • Ghamari SH, et al. "Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial." BMJ. 2023 Sep 21;382:e070464. 

  • Walsh SR, et al. "Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial." Lancet Respir Med. 2023 Sep 1 Published Online September 13, 2023 

  • Walsh SR, et al. "Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study." EClinicalMedicine. 2023 Sep 12;64:102168. eCollection 2023 Oct. 

  • Fang Y, et al. "Chatbot-Delivered Online Intervention to Promote Seasonal Influenza Vaccination During the COVID-19 Pandemic: A Randomized Clinical Trial." JAMA Netw Open. 2023 Sep 5;6(9):e2332568. (Original study) 

  • Luo C, et al. "Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies." J Infect Dis. 2023 Aug 3:jiad306. 

  • Chung MSH, et al. "Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study." PLoS Med. 2023 Jul 24;20(7):e1004274. eCollection 2023 Jul. 

  • Mashasi I, et al. "Factors associated with COVID-19 vaccine uptake among people with type 2 diabetes in Kenya and Tanzania: a mixed-methods study." BMJ Open 2023;13:e073668. Accepted 21 August 2023 doi: 10.1136/bmjopen-2023-073668. 

  • Zullo AR, et al. "Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults." JAMA Netw Open. 2023 Aug 1;6(8):e2326852. 

  • Duriseti R, et al. "Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19." July 20, 2023 N Engl J Med 2023; 389:284-286 

  • Dadoun SE, et al. "Coronavirus Disease 2019 (COVID-19) Vaccination and Assisted Reproduction Outcomes: A Systematic Review and Meta-analysis." Obstet Gynecol. 2023 Jul 13. 

  • Zhang H, et al. "The Efficacy of SARS-CoV-2 Vaccination in the Elderly: A Systemic Review and Meta-analysis." J Gen Intern Med. 2023 Jun 2. 

  • Martin-Bauta Y, et al. "A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study)." Lancet Reg Health Am. 2023 May;21:100497. Epub 2023 May 5. 

  • Wang BS, et al. "Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial." Lancet Respir Med. 2023 Mar 7:S2213-2600(23)00049-8. 

  • Alves K, et al. "Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373." March 2, 2023 N Engl J Med 2023; 388:857-859 

  • Duan M, et al. "Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines." NEJM March 1, 2023 

  • Dalvi APR, et al. "The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2 - The results of ProBCG: A Multicenter Randomized Clinical Trial in Brazil." Int J Infect Dis. 2023 Feb 23:S1201-9712(23)00065-6. 

  • Rubin E, et al. "Audio Interview: What to Expect from Covid-19 Vaccines." February 16, 2023 N Engl J Med 2023; 388:e23 

  • Ribeiro PAB, et al. "Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022." Lancet Respir Med. 2023 Feb 13 

  • Geng Y, et al. "COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis." J Immunother Cancer. 2023 Feb;11 (2):e006246. 

  • Calabro GE, et al. "Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence." Vaccines (Basel). 2023 Feb 3;11(2):347. 

As part of K2P COVID-19 Series, K2P center is pleased to launch the latest product: “A Closer Look at COVID-19 Vaccines: The Known, the Unknown, and the Uncertain”. (Arabic Version) , (English Version) , (Full Product Version)

 This is the second product on the COVID-19 Vaccine developed by K2P. To know more about the first product, you can check at: Countdown to a COVID-19 Vaccine: Spotlight on Lebanon